Home

SETH VAN VOORHEES

CIK 1284934 · CHIEF FINANCIAL OFFICER · last filed 2022-12-19

SETH VAN VOORHEES is a CHIEF FINANCIAL OFFICER who has filed 18 SEC Form 4 insider transactions across 3 companies since 2011. The most recent filing shows the insider bought $18.2K of NRXPW on Dec 19, 2022. Across all open-market trades the lifetime net is +$431.6K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $116.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$116.1K

Companies

3

Total Filings

18

Lifetime Open-Market Net

$431.6K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NRX Pharmaceuticals, Inc. (NRXPW) Delisted CHIEF FINANCIAL OFFICER 18,032 $0.00 $47 $69.4K 3 2022-12-19
PDSB Chief Financial Officer 17,647 $0.69 $12.2K $150.0K 2 2021-06-17
REFR CFO & VP-Business Development 237,793 $0.44 $103.9K $212.2K 13 2020-02-24

Recent Filings

18 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-12-19 NRX Pharmaceuticals, Inc. (NRXPW) Delisted Buy (P) +16,337 $18.2K EDGAR
2022-12-19 NRX Pharmaceuticals, Inc. (NRXPW) Delisted Buy (P) +30,000 $33.0K EDGAR
2022-11-28 NRX Pharmaceuticals, Inc. (NRXPW) Delisted Buy (P) +16,337 $18.2K EDGAR
2021-06-17 PDSB Buy (P) +17,647 $150.0K EDGAR
2021-01-06 PDSB Grant (A) — $0 EDGAR
2020-02-24 REFR Mixed +91,554 $125.0K EDGAR
2020-01-02 REFR Grant (A) — $0 EDGAR
2019-06-17 REFR Grant (A) — $0 EDGAR
2018-05-04 REFR Grant (A) — $0 EDGAR
2018-01-03 REFR Grant (A) — $0 EDGAR
Showing 1–10 of 18
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.